New insights into the burden and costs of multiple sclerosis in Europe
暂无分享,去创建一个
Jenny Berg | Alan Thompson | A. Thompson | G. Kobelt | Gisela Kobelt | J. Eriksson | Jennifer Eriksson | J. Berg | Mia Gannedahl | Mia Gannedahl | A. Thompson | A. Thompson
[1] M. Cowie. National Institute for Health and Care Excellence. , 2015, European heart journal.
[2] A. Feinstein,et al. Self-assessment of Cognition in Multiple Sclerosis: The Role of Personality and Anxiety , 2011, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.
[3] P Lindgren,et al. Costs and quality of life of patients with multiple sclerosis in Europe , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[4] G. Cutter,et al. Prevalence of multiple sclerosis symptoms across lifespan: data from the NARCOMS Registry. , 2015, Neurodegenerative disease management.
[5] M. Blair,et al. The mediating role of processing speed in the relationship between depressive symptoms and cognitive function in multiple sclerosis , 2016, Journal of clinical and experimental neuropsychology.
[6] A. Thompson,et al. A much-needed focus on progression in multiple sclerosis , 2015, The Lancet Neurology.
[7] F. Jacques. Defining the clinical course of multiple sclerosis: The 2013 revisions , 2015, Neurology.
[8] P. Rieckmann,et al. Neurologische Universitätsklinik , Rostock Costs and quality of life in multiple sclerosis An observational study in Germany , 2022 .
[9] Peter Lindgren,et al. Costs and quality of life in multiple sclerosis , 2001, The European Journal of Health Economics (HEPAC).
[10] B. Jönsson,et al. Costs, quality of life and disease severity in multiple sclerosis: a cross‐sectional study in Sweden , 2001, European journal of neurology.
[11] A. Kansal,et al. Cost-Effectiveness Analyses in Multiple Sclerosis: A Review of Modelling Approaches , 2014, PharmacoEconomics.
[12] J. Shearer,et al. Squinting Through Layers of Fog: Assessing the Cost Effectiveness of Treatments for Multiple Sclerosis , 2013, Applied Health Economics and Health Policy.
[13] G. Kobelt. Health economic issues in MS. , 2006, International MS journal.
[14] Valérie Paris,et al. Value in Pharmaceutical Pricing , 2013 .
[15] B. Jönsson. Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease. , 1996, Scandinavian journal of gastroenterology. Supplement.
[16] A. Kasuya. EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.
[17] Jacques LeLorier,et al. Future MS care: a consensus statement of the MS in the 21st Century Steering Group , 2012, Journal of Neurology.
[18] T. Friede,et al. Multiple sclerosis registries in Europe – results of a systematic survey , 2014, Multiple sclerosis.
[19] D. Goodin,et al. A comparative analysis of Patient-Reported Expanded Disability Status Scale tools , 2015, Multiple sclerosis.
[20] B. Jönsson,et al. The Economic Cost of Multiple Sclerosis in Sweden in 1994 , 1998, PharmacoEconomics.
[21] D. Amtmann,et al. Beyond depression: Predictors of self-reported cognitive function in adults living with MS. , 2015, Rehabilitation psychology.
[22] S. Mehr,et al. The Latest Innovations in the Drug Pipeline for Multiple Sclerosis. , 2015, American health & drug benefits.
[23] G. Kobelt,et al. The comparison of trial data-based and registry data-based cost-effectiveness of infliximab treatment for rheumatoid arthritis in Sweden using a modeling approach. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[24] J. G. von der Schulenburg,et al. Benefit assessment in Germany: implications for price discounts , 2016, Health Economics Review.
[25] A. Williams. EuroQol : a new facility for the measurement of health-related quality of life , 1990 .
[26] Gavin Giovannoni,et al. Brain health: time matters in multiple sclerosis. , 2016, Multiple sclerosis and related disorders.
[27] Paul Kind,et al. A social tariff for EuroQol: results from a UK general population survey , 1995 .
[28] K. Noyes,et al. Modelling the Cost Effectiveness of Disease-Modifying Treatments for Multiple Sclerosis , 2013, PharmacoEconomics.